ISRS Guideline for Primary Renal Cell Carcinoma (RCC) – A Practical Approach to SABR in your Clinic
The 2024 Lancet Oncology ISRS practice guideline for SABR in primary RCC is designed to cover key questions in the management of primary RCC. To understand the evidence base that is available to inform practice, a systematic review of all available evidence was performed. The key questions addressed included; what is the optimal dose regimen? […]
Oligometastases To and From the Lung – the Role of SABR
Oligometastatic disease is one of the most topical areas in radiation oncology in the present era. Several key trials have embedded the use of stereotactic ablative body radiotherapy (SABR) in the modern oncological armamentarium. However there are several key considerations for routine clinical practice; these include the optimal dose, sequencing, safety, combinations with systemic therapy […]
New Frontiers: SBRT for Primary Kidney Cancers
Primary kidney cancer has historically been considered a resistant tumour to radiotherapy. However, with the incidence of primary kidney cancers increasing in the developed world at the same time as an increase in life expectancy and prevalence of obesity, there are a growing number of patients who may present with inoperable primary kidney cancer. Advances […]